Eli Lilly and Company’s LLY stock has declined 15.7% in the past year. The first-quarter earnings miss, guidance cut and some positive developments at rival Novo Nordisk NVO were the primary reasons ...

As demand soars for weight loss medications, so has the competition. Eli Lilly slashed prices for its hugely successful obesity medication, Zepbound. This comes at a time when compounded GLP-1 ...

Both Eli Lilly LLY and Merck MRK are major players in the U.S. pharmaceutical industry, developing and commercializing ...

Eli Lilly's blockbuster weight loss drug Zepbound and diabetes treatment Mounjaro posted weaker-than-expected sales for the third quarter, even as supply of both medicines has largely recovered ...

Eli Lilly's weight loss drugs, especially Zepbound and Mounjaro, have driven impressive revenue growth. Click here to read an ...

Eli Lilly LLY will report its third-quarter 2024 earnings on Oct. 30, before market open. The Zacks Consensus Estimate for sales and earnings is pegged at $12.03 billion and $1.53 per share ...

Eli Lilly & Co. broadened its effort to crack down on fake and off-brand versions of hit obesity drug Zepbound, saying it has filed more lawsuits against companies selling compounded versions of ...

Eli Lilly & Co. broadened its effort to crack down on fake and off-brand versions of hit obesity drug Zepbound, saying it has filed more lawsuits against companies selling compounded versions of ...

Now, one of those drugs, Eli Lilly's Zepbound, is being studied for use as an anti-inflammatory treatment for psoriasis, a condition that North Chicago-based AbbVie treats with Humira and other ...